Pipeline

We are using our multiple discovery platforms to develop disease-altering therapies for conditions with high unmet medical need. Our ATRIVIEW® drug discovery platform focuses on diseases of the central nervous system. It discovers drug leads for neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis. Our SHINE MOUSE® and NuvoMab™ platform generate antibodies to treat various types of cancer, reaching difficult-to-drug targets with high selectivity and affinity.
Central Nervous System
SNR1611
Amyotrophic Lateral Sclerosls (ALS)

Discovery Research

Preclinical

IND
Enabling

Phase I

Phase II

Phase III

MEK1/2 Inhibitor

Additional Indication
for approved drug

Oral

SNR1611
Alzheimer’s Disease

Discovery Research

Preclinical

IND
Enabling

Phase I

Phase II

Phase III

MEK1/2 Inhibitor

Additional Indication
for approved drug

Oral

GNUV101
Neurodegenerative Disease

Discovery Research

Preclinical

IND
Enabling

Phase I

Phase II

Phase III

MEK1/2 Inhibitor

New chemical entities

Oral

Immuno-oncology
GNUV201
Undisclosed Solid Tumor

Discovery Research

Preclinical

IND
Enabling

Phase I

Phase II

Phase III

PD-1 target

Biologics

Injection

GNUV202
Undisclosed Solid Tumor

Discovery Research

Preclinical

IND
Enabling

Phase I

Phase II

Phase III

CCR-8 target

Biologics

Injection

GNUV203
Undisclosed Solid Tumor

Discovery Research

Preclinical

IND
Enabling

Phase I

Phase II

Phase III

Target undisclosed

Biologics

Injection

GNUV204
Undisclosed Solid Tumor

Discovery Research

Preclinical

IND
Enabling

Phase I

Phase II

Phase III

IL-2, Fc-fused

Biologics

Injection

GNUV205
Undisclosed Solid Tumor

Discovery Research

Preclinical

IND
Enabling

Phase I

Phase II

Phase III

IL-2 fused to anti-PD-1

Biologics

Injection

The information contained herein is subject to change as the drug development progresses. Genuv makes every effort to continuously update the information published on this page; and reserves the right to amend above information at anytime and without any prior announcement. Genuv, however, does not undertake any obligation to guarantee the correctness, up-to-dateness, and completeness of the above information provided above.